JPRN-UMIN000001827招募中未知
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with Cancer - Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with Cancer (TUTRCDC001)
Tohoku University Translational Research Center0 个研究点目标入组 90 人开始时间: 2009年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Without active interstitial pneumonitis or uncontrollable lung fibrosis (2) No concurrent thoracic radiotherapy during chemotherapy; (3) Without uncontrollable infectious disease; (4) No severe complication including heart failure, renal insufficiency, liver dysfunction, hemorrhagic digestive tract ulcer, ileus, and uncontrollable diabetic mellitus (5) Without pregnancy or nurse (6) No uncontrollable mental disease (7) No inappropriate patient judged by a medical doctor for enrollment into this study
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected SubjectEUCTR2004-001779-20-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582192
进行中（未招募）
1 期
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
已完成
3 期
A phase III study of ONO-4538(ONO-4538-52/TASUKI-52)JPRN-jRCT2080223505ONO PHARMACEUTICAL CO.,LTD.530
未知
3 期
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast CancerBreast Cancer MetastasisJPRN-jRCT2080220407AstraZeneca
尚未招募
2 期
BeatNF2 trialJPRN-jRCT2080224914Kiyoshi Saito60